Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hida, T.
Right arrow Articles by Takahashi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hida, T.
Right arrow Articles by Takahashi, T.
Clinical Cancer Research Vol. 6, 2006-2011, May 2000
© 2000 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Cyclooxygenase-2 Inhibitor Induces Apoptosis and Enhances Cytotoxicity of Various Anticancer Agents in Non-Small Cell Lung Cancer Cell Lines1

Toyoaki Hida2, Ken-ichi Kozaki, Hideki Muramatsu, Akira Masuda, Shigeki Shimizu, Tetsuya Mitsudomi, Takahiko Sugiura, Makoto Ogawa and Takashi Takahashi

Departments of Internal Medicine [T. H., H. M., T. S., M. O.] and Thoracic Surgery [S. S., T. M.], Aichi Cancer Center Hospital; and Laboratory of Ultrastructure Research [A. M., T. T.] and Pathophysiology Unit [K. K., T. T.], Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan

In recent years, a combination of two demographic phenomena, an increase in the number of older people in the population and an increase in the incidence of lung cancer with age, has made it mandatory to develop therapeutic modalities with less toxicity for the treatment of inoperable elderly patients with lung cancer. Our study shows that a cyclooxygenase (COX)-2 inhibitor, nimesulide, can inhibit proliferation of non-small cell lung cancer cell lines in vitro in a dose-dependent manner, in part by inducing apoptosis even at clinically achievable low concentrations. Our observations also suggest that the responsiveness of non-small cell lung cancer to COX-2 inhibitors does not require the presence of wild-type p53, but may be influenced by the degree of COX-2 expression. In addition, we found that nimesulide, when used in combination at clinically achievable concentrations, reduced the IC50 values of various anticancer agents by up to 77%, although the level of reduction varied considerably. Because our previous studies have indicated a significantly increased COX-2 expression in up to 70% of adenocarcinoma cases, the present findings are of great clinical interest. In conjunction with the recent development of next generation, highly selective COX-2 inhibitors, they can be expected to lead to even greater efficacy of their use as adjuncts to various anticancer agents for the treatment of high-risk patients without compromising their quality of life.




This article has been cited by other articles:


Home page
 Mol. Cell. ProteomicsHome page
A. J. VanMeter, A. S. Rodriguez, E. D. Bowman, J. Jen, C. C. Harris, J. Deng, V. S. Calvert, A. Silvestri, C. Fredolini, V. Chandhoke, et al.
Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer: Differential Epidermal Growth Factor Receptor (EGPR) Phosphorylation Events Associated with Mutated EGFR Compared with Wild Type
Mol. Cell. Proteomics, October 1, 2008; 7(10): 1902 - 1924.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. Alam, J. H. Wang, J. C. Coffey, S. S. Qadri, A. O'Donnell, T. Aherne, and H. P. Redmond
Characterization of the Effects of Cyclooxygenase-2 Inhibition in the Regulation of Apoptosis in Human Small and Non Small Cell Lung Cancer Cell Lines
Ann. Surg. Oncol., September 1, 2007; 14(9): 2678 - 2684.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Jimeno, M. L. Amador, P. Kulesza, X. Wang, B. Rubio-Viqueira, X. Zhang, A. Chan, J. Wheelhouse, H. Kuramochi, K. Tanaka, et al.
Assessment of celecoxib pharmacodynamics in pancreatic cancer
Mol. Cancer Ther., December 1, 2006; 5(12): 3240 - 3247.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
F. Cianchi, C. Cortesini, L. Magnelli, E. Fanti, L. Papucci, N. Schiavone, L. Messerini, A. Vannacci, S. Capaccioli, F. Perna, et al.
Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells.
Mol. Cancer Ther., November 1, 2006; 5(11): 2716 - 2726.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. Csiki and D. H. Johnson
Did Targeted Therapy Fail Cyclooxygenase Too?
J. Clin. Oncol., October 20, 2006; 24(30): 4798 - 4800.
[Full Text] [PDF]

Home page
 JCOHome page
R. Lilenbaum, M. A. Socinski, N. K. Altorki, L. L. Hart, R. S. Keresztes, S. Hariharan, M. E. Morrison, R. Fayyad, and P. Bonomi
Randomized Phase II Trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan With or Without Celecoxib in the Second-Line Treatment of Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 20, 2006; 24(30): 4825 - 4832.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Upadhyay, C. Liu, A. Chatterjee, M. O. Hoque, M. S. Kim, J. Engles, W. Westra, B. Trink, E. Ratovitski, and D. Sidransky
LKB1/STK11 Suppresses Cyclooxygenase-2 Induction and Cellular Invasion through PEA3 in Lung Cancer
Cancer Res., August 15, 2006; 66(16): 7870 - 7879.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. T. Mao, M. C. Fishbein, B. Adams, M. D. Roth, L. Goodglick, L. Hong, M. Burdick, E. R. M. Strieter, C. Holmes, D. P. Tashkin, et al.
Celecoxib Decreases Ki-67 Proliferative Index in Active Smokers
Clin. Cancer Res., January 1, 2006; 12(1): 314 - 320.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Xi, S. E. Baldus, U. Warnecke-Eberz, J. Brabender, S. Neiss, R. Metzger, F. C. Ling, H. P. Dienes, E. Bollschweiler, S. Moenig, et al.
High Cyclooxygenase-2 Expression Following Neoadjuvant Radiochemotherapy Is Associated with Minor Histopathologic Response and Poor Prognosis in Esophageal Cancer
Clin. Cancer Res., December 1, 2005; 11(23): 8341 - 8347.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
C. Mascaux, B. Martin, J-M. Verdebout, V. Ninane, and J-P. Sculier
COX-2 expression during early lung squamous cell carcinoma oncogenesis
Eur. Respir. J., August 1, 2005; 26(2): 198 - 203.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H M. Prince, L. Mileshkin, A. Roberts, V. Ganju, C. Underhill, J. Catalano, R. Bell, J. F. Seymour, D. Westerman, P. J. Simmons, et al.
A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma
Clin. Cancer Res., August 1, 2005; 11(15): 5504 - 5514.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Sharma, L. Zhu, S. C. Yang, L. Zhang, J. Lin, S. Hillinger, B. Gardner, K. Reckamp, R. M. Strieter, M. Huang, et al.
Cyclooxygenase 2 Inhibition Promotes IFN-{gamma}-Dependent Enhancement of Antitumor Responses
J. Immunol., July 15, 2005; 175(2): 813 - 819.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
E. M. Sievers, R. D. Bart, L. M. Backhus, Y. Lin, M. Starnes, R. Castanos, V. A. Starnes, and Ross. M. Bremner
Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of lung cancer for dose-dependent effect
J. Thorac. Cardiovasc. Surg., June 1, 2005; 129(6): 1242 - 1249.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z. Liao, R. Komaki, L. Milas, C. Yuan, M. Kies, J. Y. Chang, M. Jeter, T. Guerrero, G. Blumenschien, C. M. Smith, et al.
A Phase I Clinical Trial of Thoracic Radiotherapy and Concurrent Celecoxib for Patients with Unfavorable Performance Status Inoperable/Unresectable Non-Small Cell Lung Cancer
Clin. Cancer Res., May 1, 2005; 11(9): 3342 - 3348.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Uchida, S. Schneider, J. M. Yochim, H. Kuramochi, K. Hayashi, K. Takasaki, D. Yang, K. D. Danenberg, and P. V. Danenberg
Intratumoral COX-2 Gene Expression Is a Predictive Factor for Colorectal Cancer Response to Fluoropyrimidine-Based Chemotherapy
Clin. Cancer Res., May 1, 2005; 11(9): 3363 - 3368.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. A. Khuder, N. A. Herial, A. B. Mutgi, and D. J. Federman
Nonsteroidal Antiinflammatory Drug Use and Lung Cancer: A Metaanalysis
Chest, March 1, 2005; 127(3): 748 - 754.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Gasparini, R. Longo, M. Fanelli, and B. A. Teicher
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
J. Clin. Oncol., February 20, 2005; 23(6): 1295 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. T. Mao, I-H. Tsu, S. M. Dubinett, B. Adams, T. Sarafian, F. Baratelli, M. D. Roth, and K. J. Serio
Modulation of Pulmonary Leukotriene B4 Production by Cyclooxygenase-2 Inhibitors and Lipopolysaccharide
Clin. Cancer Res., October 15, 2004; 10(20): 6872 - 6878.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. R. Brown and R. N. DuBois
Cyclooxygenase as a Target in Lung Cancer
Clin. Cancer Res., June 15, 2004; 10(12): 4266S - 4269S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. R. Brown and R. N. DuBois
Cyclooxygenase-2 in Lung Carcinogenesis and Chemoprevention: Roger S. Mitchell Lecture
Chest, May 1, 2004; 125(5_suppl): 134S - 140S.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Pold, L. X. Zhu, S. Sharma, M. D. Burdick, Y. Lin, P. P. N. Lee, A. Pold, J. Luo, K. Krysan, M. Dohadwala, et al.
Cyclooxygenase-2-Dependent Expression of Angiogenic CXC Chemokines ENA-78/CXC Ligand (CXCL) 5 and Interleukin-8/CXCL8 in Human Non-Small Cell Lung Cancer
Cancer Res., March 1, 2004; 64(5): 1853 - 1860.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. Shaik, A. Chatterjee, and M. Singh
Effect of a Selective Cyclooxygenase-2 Inhibitor, Nimesulide, on the Growth of Lung Tumors and Their Expression of Cyclooxygenase-2 and Peroxisome Proliferator- Activated Receptor-{gamma}
Clin. Cancer Res., February 15, 2004; 10(4): 1521 - 1529.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. Campa, S. Zienolddiny, V. Maggini, V. Skaug, A. Haugen, and F. Canzian
Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer
Carcinogenesis, February 1, 2004; 25(2): 229 - 235.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. T. Mao, M. D. Roth, K. J. Serio, F. Baratelli, L. Zhu, E. C. Holmes, R. M. Strieter, and S. M. Dubinett
Celecoxib Modulates the Capacity for Prostaglandin E2 and Interleukin-10 Production in Alveolar Macrophages from Active Smokers
Clin. Cancer Res., December 1, 2003; 9(16): 5835 - 5841.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Makowski, T. Grzela, J. Niderla, M. Lazarczyk, P. Mroz, M. Kopee, M. Legat, K. Strusinska, K. Koziak, D. Nowis, et al.
Inhibition of Cyclooxygenase-2 Indirectly Potentiates Antitumor Effects of Photodynamic Therapy in Mice
Clin. Cancer Res., November 1, 2003; 9(14): 5417 - 5422.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. E. Castelao, R. D. Bart III, C. A. DiPerna, E. M. Sievers, and R. M. Bremner
Lung cancer and cyclooxygenase-2
Ann. Thorac. Surg., October 1, 2003; 76(4): 1327 - 1335.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Ferrandina, F. O. Ranelletti, F. Legge, L. Lauriola, V. Salutari, M. Gessi, A. C. Testa, U. Werner, P. Navarra, G. Tringali, et al.
Celecoxib Modulates the Expression of Cyclooxygenase-2, Ki67, Apoptosis-Related Marker, and Microvessel Density in Human Cervical Cancer: A Pilot Study
Clin. Cancer Res., October 1, 2003; 9(12): 4324 - 4331.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Dmitrovsky
Combining Cytotoxic Chemotherapy With Cyclooxygenase-2 Inhibition
J. Clin. Oncol., July 15, 2003; 21(14): 2631 - 2632.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. J. Henry, D. L. McCaw, S. E. Turnquist, J. W. Tyler, L. Bravo, S. Sheafor, R. C. Straw, W. S. Dernell, B. R. Madewell, L. Jorgensen, et al.
Clinical Evaluation of Mitoxantrone and Piroxicam in a Canine Model of Human Invasive Urinary Bladder Carcinoma
Clin. Cancer Res., February 1, 2003; 9(2): 906 - 911.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Dohadwala, R. K. Batra, J. Luo, Y. Lin, K. Krysan, M. Pold, S. Sharma, and S. M. Dubinett
Autocrine/Paracrine Prostaglandin E2 Production by Non-small Cell Lung Cancer Cells Regulates Matrix Metalloproteinase-2 and CD44 in Cyclooxygenase-2-dependent Invasion
J. Biol. Chem., December 20, 2002; 277(52): 50828 - 50833.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. S. A. Qadri, J. H. Wang, K. C. Redmond, A. F. O'Donnell, T. Aherne, and H. P. Redmond
The role of COX-2 inhibitors in lung cancer
Ann. Thorac. Surg., November 1, 2002; 74(5): 1648 - 1652.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Ferrandina, L. Lauriola, G. F. Zannoni, A. Fagotti, F. Fanfani, F. Legge, N. Maggiano, M. Gessi, S. Mancuso, F. O. Ranelletti, et al.
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients
Ann. Onc., August 1, 2002; 13(8): 1205 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Ferrario, K. von Tiehl, S. Wong, M. Luna, and C. J. Gomer
Cyclooxygenase-2 Inhibitor Treatment Enhances Photodynamic Therapy-mediated Tumor Response
Cancer Res., July 15, 2002; 62(14): 3956 - 3961.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Dy and A. A. Adjei
Novel Targets for Lung Cancer Therapy: Part II
J. Clin. Oncol., July 1, 2002; 20(13): 3016 - 3028.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Hida, K.-i. Kozaki, H. Ito, O. Miyaishi, Y. Tatematsu, T. Suzuki, K. Matsuo, T. Sugiura, M. Ogawa, T. Takahashi, et al.
Significant Growth Inhibition of Human Lung Cancer Cells Both in Vitro and in Vivo by the Combined Use of a Selective Cyclooxygenase 2 Inhibitor, JTE-522, and Conventional Anticancer Agents
Clin. Cancer Res., July 1, 2002; 8(7): 2443 - 2447.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. G. Edwards, S. P. Faux, S. M. Plummer, K. R. Abrams, R. A. Walker, D. A. Waller, and K. J. O'Byrne
Cyclooxygenase-2 Expression Is a Novel Prognostic Factor in Malignant Mesothelioma
Clin. Cancer Res., June 1, 2002; 8(6): 1857 - 1862.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. S. Ettinger
Is There a Preferred Combination Chemotherapy Regimen for Metastastic Non-Small Cell Lung Cancer?
Oncologist, June 1, 2002; 7(3): 226 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
J. M. Wallace
Nutritional and Botanical Modulation of the Inflammatory Cascade--Eicosanoids, Cyclooxygenases, and Lipoxygenases-- As an Adjunct in Cancer Therapy
Integr Cancer Ther, March 1, 2002; 1(1): 7 - 37.
[Abstract] [PDF]

Home page
 Am. J. Pathol.Home page
T. Niki, T. Kohno, S. Iba, Y. Moriya, Y. Takahashi, M. Saito, A. Maeshima, T. Yamada, Y. Matsuno, M. Fukayama, et al.
Frequent Co-Localization of Cox-2 and Laminin-5 {gamma}2 Chain at the Invasive Front of Early-Stage Lung Adenocarcinomas
Am. J. Pathol., March 1, 2002; 160(3): 1129 - 1141.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Ferrandina, L. Lauriola, M. G. Distefano, G. F. Zannoni, M. Gessi, F. Legge, N. Maggiano, S. Mancuso, A. Capelli, G. Scambia, et al.
Increased Cyclooxygenase-2 Expression Is Associated With Chemotherapy Resistance and Poor Survival in Cervical Cancer Patients
J. Clin. Oncol., February 15, 2002; 20(4): 973 - 981.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. D. Blumenthal, C. Waskewich, D. M. Goldenberg, W. Lew, C. Flefleh, and J. Burton
Chronotherapy and Chronotoxicity of the Cyclooxygenase-2 Inhibitor, Celecoxib, in Athymic Mice Bearing Human Breast Cancer Xenografts
Clin. Cancer Res., October 1, 2001; 7(10): 3178 - 3185.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Oshima, N. Murai, S. Kargman, M. Arguello, P. Luk, E. Kwong, M. M. Taketo, and J. F. Evans
Chemoprevention of Intestinal Polyposis in the Apc{{Delta}}716 Mouse by Rofecoxib, a Specific Cyclooxygenase-2 Inhibitor
Cancer Res., February 1, 2001; 61(4): 1733 - 1740.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
M. Dohadwala, J. Luo, L. Zhu, Y. Lin, G. J. Dougherty, S. Sharma, M. Huang, M. Pold, R. K. Batra, and S. M. Dubinett
Non-small Cell Lung Cancer Cyclooxygenase-2-dependent Invasion Is Mediated by CD44
J. Biol. Chem., June 8, 2001; 276(24): 20809 - 20812.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.